This indication represents an important advantage, as three months of DAPT may be the shortest duration required for any major drug eluting stent offered in Europe. Long-term compliance to DAPT can be a problem for patients and may lead to additional safety dangers such as increased bleeding events. Furthermore, having a shorter DAPT duration after stent implantation could be helpful in case a patient must interrupt or discontinue the medication ahead of surgery or for additional factors. ‘With XIENCE Xpedition’s exceptional deliverability, broad size matrix and the option to discontinue or interrupt DAPT after three months, physicians in Europe will have a new, comprehensive offering to handle the issues of treating individuals with complex coronary artery disease,’ said Charles A.